June a Big Month for VeriSIm Life

VeriSim Life, the Serra Capital III and Serra Capital III SBIC portfolio company, had a tremendous month in June. CEO Jo Varshney made the Inc. Female Founders 500 List. Beyond just numbers and revenue, this list recognizes founders who pushed their businesses forward in unique ways.

Also at the end of June, VeriSim announced that it had formalized a research collaboration with FDA/NCTR, in order to advance the next generation of mechanistic AI for drug development.

Drug development remains one of the most resource-intensive and failure-prone endeavors in modern science. Despite significant advances in artificial intelligence and computational chemistry, the fundamental translational gap between preclinical models and human clinical outcomes persists, contributing to late-stage failure rates that cost the industry hundreds of billions of dollars annually.

VeriSIM Life was founded to solve that problem. "BIOiSIM was built on the belief that AI should do more than generate predictions. It should explain the biology behind them and provide evidence scientists can trust. Our collaboration with FDA/NCTR advances that vision by strengthening the scientific foundation for more predictive, transparent, and human relevant drug development,” said Jo Varshney, DVM/PhD, Founder & CEO, VeriSIM Life.